SCHEMBL1905014

SCHEMBL1905014

c1ccc(-n2nccc2C2CC2)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 2/20 0.50
KEAP1 Q14145 1/20 0.45
NFE2L2 Q16236 1/20 0.45
HCRTR1 O43613 1/20 0.41
HCRTR2 O43614 1/20 0.41
DRD2 P14416 1/20 0.39
DRD3 P35462 1/20 0.39
CYP2C9 P11712 4/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
LMNA P02545 2/20 0.39
NPC1 O15118 1/20 0.39
TP53 P04637 1/20 0.39
PKM P14618 1/20 0.39
RAB9A P51151 1/20 0.39
SLC9A1 P19634 1/20 0.38
SLC9A2 Q9UBY0 1/20 0.38
KDM4E B2RXH2 2/20 0.37
HTT P42858 1/20 0.37
PDE10A Q9Y233 2/20 0.36
ALDH1A1 P00352 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23276373 0.81 KDM4E (0.35) POLBKEAP1NFE2L2HCRTR1HCRTR2
SCHEMBL6467002 0.78 OXTR (0.40) POLBHCRTR1HCRTR2SMN1; SMN2NPC1
SCHEMBL27082246 0.78 CCNB2 (0.35) DRD2DRD3KDM4EHTTALDH1A1
SCHEMBL27082622 0.78 ALDH1A1 (0.42) SMN1; SMN2KDM4EHTTALDH1A1NPSR1
SCHEMBL6370702 0.78 RAB9A (0.40) POLBNPC1TP53RAB9AKDM4E
SCHEMBL28795630 0.77 POLB (0.50) POLBHCRTR1HCRTR2DRD3CYP2C9
SCHEMBL31465895 0.74 SCN5A (0.41) POLBALDH1A1
SCHEMBL23281880 0.72 LPL (0.40) KDM4EHTTCA9
SCHEMBL16827933 0.72 PLAT (0.43) PKMALDH1A1KHKTDP1
SCHEMBL16827766 0.72 MAPKAPK2 (0.43) SMN1; SMN2TP53PKMALDH1A1TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8455477-B2 Therapeutic compounds MERCK SHARP & DOHME CORP. (US) 2013-06-04 US disclosed
US-20110207711-A1 Therapeutic Compounds MSD K.K. (JP) 2011-08-25 US disclosed
EP-2320907-A1 THERAPEUTIC COMPOUNDS Merck & Co., Inc. (US) 2011-05-18 EP disclosed
WO-2010017047-A1 THERAPEUTIC COMPOUNDS MERCK & CO., INC. (US) 2010-02-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110207711-A1 Therapeutic Compounds WEE2, MARK3, WEE1 POLB 4428/4885KEAP1 422/4885NFE2L2 1157/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.